Veracyte Inc. (VCYT)
Veracyte (VCYT) Q1 Earnings and Revenues Beat Estimates
Veracyte (VCYT) came out with quarterly earnings of $0.31 per share, beating the Zacks Consensus Estimate of $0.20 per share. This compares to loss of $0.02 per share a year ago.
Should You Continue to Hold Veracyte Stock in Your Portfolio?
Strength in the Afirma and Decipher franchises continues to bode well for VCYT stock.
Why Veracyte (VCYT) is a Top Momentum Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Here's Why Veracyte (VCYT) is a Strong Growth Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Veracyte (VCYT) Just Overtook the 20-Day Moving Average
After reaching an important support level, Veracyte (VCYT) could be a good stock pick from a technical perspective. VCYT surpassed resistance at the 20-day moving average, suggesting a short-term bullish trend.
Strength Seen in Veracyte (VCYT): Can Its 13.0% Jump Turn into More Strength?
Veracyte (VCYT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
Veracyte (VCYT) Up 0.7% Since Last Earnings Report: Can It Continue?
Veracyte (VCYT) reported earnings 30 days ago. What's next for the stock?
Wall Street Analysts Believe Veracyte (VCYT) Could Rally 35.05%: Here's is How to Trade
The mean of analysts' price targets for Veracyte (VCYT) points to a 35.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Veracyte Stock Surges 45.6% in a Year: What's Driving the Rally?
Strength in VCYT's Afirma and Decipher tests continues to draw investors' attention.
Solid Growth, Soft Outlook: Why I'm Holding On Veracyte
Veracyte, Inc. shows strong revenue growth and market share in genomic diagnostics, particularly with its Decipher and Afirma tests, but faces significant near-term challenges. 2024 ended positively with 23% revenue growth and strong cash flow, yet 2025 will be critical for transitioning to a stable, profit-generating leader. Regulatory uncertainties, Afirma's growth deceleration, and potential financial issues from selling the French subsidiary pose risks to Veracyte's near-term performance.
Veracyte Stock Falls Despite Q4 Earnings and Revenue Beat
VCYT registers robust growth from its market-leading Decipher Prostate and Afirma tests.
Veracyte, Inc. (VCYT) Q4 2024 Earnings Call Transcript
Veracyte, Inc. (NASDAQ:VCYT ) Q4 2024 Earnings Conference Call February 24, 2025 4:30 PM ET Company Participants Shayla Gorman - Senior Director of Investor Relations Marc Stapley - Chief Executive Officer Rebecca Chambers - Chief Financial Officer Conference Call Participants Doug Schenkel - Wolfe Research, LLC Mason Carrico - Stephens Inc. Puneet Souda - Leerink Partners Maggie Boeye - William Blair & Company Lu Li - UBS Group AG Corey Rosenbaum - Scotiabank Subbu Nambi - Guggenheim Securities, LLC Yuko Oku - Morgan Stanley Joseph Conway - Needham & Company, LLC Prashant Kota - Goldman Sachs Operator Good day, and thank you for standing by. Welcome to the Veracyte Fourth Quarter and Full Year 2024 Financial Results webcast.
